The clinical impact of frailty in transplant ineligible patients with multiple myeloma treated with bortezomib-based chemotherapy as front line therapy

被引：0

作者：

Lee, Ho Sup ^{[1
]}

Kim, Da Jung ^{[1
]}

Lee, Ji Hyun ^{[2
]}

Lee, Je-Jung ^{[3
]}

Jung, Sung-Hoon ^{[3
]}

Jo, Jae-Cheol ^{[4
]}

Lee, Yoo Jin ^{[4
]}

Shin, Ho-Jin ^{[5
]}

Lee, Won ^{[6
]}

机构：

[1] Kosin Univ, Coll Med, Busan, South Korea

[2] Dong A Univ, Coll Med, Busan, South Korea

[3] Chonnam Natl Univ, Hwasun Hosp, Hwasun Gun, Jeollanam Do, South Korea

[4] Ulsan Univ Hosp, Ulsan, South Korea

[5] Pusan Natl Univ Hosp, Busan, South Korea

[6] Busan Paik Hosp, Busan, South Korea

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

bortezomib; frailty; Multiple myeloma;

D O I：

10.1016/j.clml.2019.09.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-015

引用

页码：E11 / E12

页数：2

共 50 条

[1] The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness
Lee, Ji Hyun
Kim, Sung-Hyun
Huh, Seok Jae
Jo, Jae-Cheol
Shin, Ho-Jin
Lee, Won-Sik
Lee, Yoojin
Lee, Ho Sup
BLOOD, 2018, 132
[2] BORTEZOMIB-BASED THERAPY IN FRAIL MULTIPLE MYELOMA PATIENTS
Antonioli, E.
Staderini, M.
Nozzoli, C.
Bacchiarri, F.
Barone, F.
Grieco, P.
Coltro, G.
Guarrera, A.
Messeri, M.
Bosi, A.
HAEMATOLOGICA, 2017, 102 : 132 - 132
[3] Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy
Xu, Yan
Deng, Shuhui
An, Gang
Li, Zengjun
Qin, Xiaoqi
Sui, Weiwei
Feng, Xiaoyan
Zou, Dehui
Qiu, Lugui
BLOOD, 2015, 126 (23)
[4] Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial
Atsushi Isoda
Kayoko Murayama
Shigeki Ito
Yoichi Kohara
Masaki Iino
Yuri Miyazawa
Morio Matsumoto
Hiroshi Handa
Yosuke Imai
Takuro Ishiguro
Wataru Izumita
Kiyoshi Kitano
Yukio Hirabayashi
Hideyuki Nakazawa
Fumihiro Ishida
Toru Mitsumori
Keita Kirito
Takaaki Chou
Hirokazu Murakami
International Journal of Hematology, 2018, 108 : 39 - 46
[5] Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial
Isoda, Atsushi
Murayama, Kayoko
Ito, Shigeki
Kohara, Yoichi
Iino, Masaki
Miyazawa, Yuri
Matsumoto, Morio
Handa, Hiroshi
Imai, Yosuke
Ishiguro, Takuro
Izumita, Wataru
Kitano, Kiyoshi
Hirabayashi, Yukio
Nakazawa, Hideyuki
Ishida, Fumihiro
Mitsumori, Toru
Kirito, Keita
Chou, Takaaki
Murakami, Hirokazu
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (01) : 39 - 46
[6] The first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma
Ho, C-L.
Chen, J-H.
ANNALS OF ONCOLOGY, 2019, 30
[7] Clinical outcomes of bortezomib-based therapy in myeloma
Djebbari, Faouzi
Srinivasan, Anandagopal
Valiance, Grant
Moore, Sally
Kothari, Jaime
Ramasamy, Karthik
PLOS ONE, 2018, 13 (12):
[8] Dramatic results seen in phase III front-line multiple myeloma trials of bortezomib-based therapy
不详
ONCOLOGY-NEW YORK, 2008, 22 (01): : 80 - 81
[9] Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction
Mollee, Peter
Boyle, Stephen
Wellard, Cameron
Moore, Elizabeth
Blacklock, Hilary
Harrison, Simon J.
Ho, P. Joy
Hocking, Jay
McQuilten, Zoe
Quach, Hang
Spearing, Ruth
Wood, Erica
Spencer, Andrew
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E233 - E234
[10] Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma
Ludwig, Heinz
Drach, Johannes
Graf, Helmut
Lang, Alois
Meran, Johannes Gobertus
HAEMATOLOGICA, 2007, 92 (10) : 1411 - 1414

← 1 2 3 4 5 →